EYPT Q1 2022 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M+26.9% YoY

Gross Profit

$8M80.9% margin

Operating Income

-$18M-196.7% margin

Net Income

-$21M-225.7% margin

EPS (Diluted)

$-0.60

QoQ Revenue Growth

-19.5%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$245M

Total Liabilities

$78M

Stockholders' Equity

$167M

Cash & Equivalents

$102M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$7M	+26.9%
Gross Profit	$8M	$6M	+26.7%
Operating Income	-$18M	-$11M	-67.2%
Net Income	-$21M	-$12M	-70.8%

Revenue Segments

Y U T I Q Product

$5M51%

D E X Y C U Product

$4M49%